Rankings
▼
Calendar
JAZZ Q1 2025 Earnings — Jazz Pharmaceuticals plc Revenue & Financial Results | Market Cap Arena
JAZZ
Jazz Pharmaceuticals plc
$12B
Q1 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$898M
-0.5% YoY
Gross Profit
$793M
88.3% margin
Operating Income
-$56M
-6.2% margin
Net Income
-$93M
-10.3% margin
EPS (Diluted)
$-1.52
QoQ Revenue Growth
-17.5%
Cash Flow
Operating Cash Flow
$430M
Free Cash Flow
$391M
Stock-Based Comp.
$68M
Balance Sheet
Total Assets
$11.5B
Total Liabilities
$7.4B
Stockholders' Equity
$4.2B
Cash & Equivalents
$1.9B
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$898M
$902M
-0.5%
Gross Profit
$793M
$806M
-1.6%
Operating Income
-$56M
$66M
-184.4%
Net Income
-$93M
-$15M
-533.1%
Revenue Segments
Xywav
$345M
38%
Epidiolex/Epidyolex
$218M
24%
Rylaze/Enrylaze
$94M
10%
Zepzelca
$63M
7%
High Sodium AG Oxybate Product Royalty Revenue
$49M
5%
Defitelio/Defibrotide
$41M
5%
Xyrem
$37M
4%
Vyxeos
$30M
3%
Other Royalty And Contract Revenues
$9M
1%
Sativex
$5M
1%
Other Products
$5M
1%
Ziihera
$2M
0%
Geographic Segments
UNITED STATES
$798M
89%
Europe
$84M
9%
Other Countries
$16M
2%
← FY 2025
All Quarters
Q2 2025 →